Following the failure of Nano Silver Experimental Drugs to sail  through screening by the National Health Research Ethics Committee, the Federal Government is now to commence pre-clinical studies of drugs’ claims. Co-Chairman of the Treatment Research Group Committee on Ebola Virus Disease (EVD), Prof. Karniyus Gamaniel said, the new trials and studies will bridge the gap caused by the failure of the Nano Silver drugs.

Speaking on the way forward, going by the Nano Silver flip – flop, he said “we are actually working hard to bridge the gap.” Gamaniel,  who is also the Director General of the National Institute of Pharmaceutical Research and Development (NIPRD, said “we are commencing the examination of pre-clinical studies of some low hanging drugs (trial drugs closed to being used by humans).” Doing the pre-clinical studies will enable the administration of the drugs on humans” as part of treatment for Ebola virus.

No Comments

Leave a Comment